BioBlast PharmaPrint Page  |  Close Window

Investors Overview

About Us

Bioblast Pharma is a publicly traded, clinical-stage biotechnology company (NASDAQ - "ORPN") committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.

Our therapeutic platforms are based on deep understanding of the disease-causing biological processes, and can potentially offer solutions for several diseases that share the same biological pathology.

Given the interest in the scientific and medical community regarding alternative therapeutic uses of our lead drug candidate, trehalose 90mg/mL IV solution, Bioblast has decided to postpone work on our other therapeutic platforms and to concentrate internal development efforts exclusively on trehalose.

The company is led by a management team experienced in the development and commercialization of disease therapeutics.

Read More

Events

There are currently no events scheduled.

More Events

Patients and caregivers affected by OPMD tell their personal stories and how they live with OPMD

News

Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger OpportunitiesJune 05, 2017
JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel, June 0... 
Bioblast Pharma Reports First Quarter 2017 Financial ResultsMay 26, 2017
TEL AVIV, Israel, May 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announ... 
Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid RequirementsApril 17, 2017
TEL AVIV, Israel, April 17, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced ... 
More News